Comparison
Bromantane vs Citicoline
Side-by-side of Bromantane and Citicoline. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Bromantane
Bromantane, the Russian nootropic sold as Ladasten (ADK-709), acts on dopamine to cut fatigue and anxiety without classical stimulant rebound.
Citicoline
Citicoline supplement profile: CDP-choline as a phosphatidylcholine precursor, Cognizin dosing 250-2000 mg, cognition trials, stroke recovery evidence.
Effects at a glance
Bromantane
- •Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
- •Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
- •Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
- •Long half-life of around 11 hours supports once-daily morning dosing
- •WADA-banned since 1996; relevant for tested athletes
- •Western evidence base is thin; most published trials are Russian-language and not independently replicated
Citicoline
- •Choline donor and phosphatidylcholine precursor; oral bioavailability roughly 99%
- •Standard prescription medication for stroke recovery and vascular cognitive impairment in much of the world
- •Healthy-adult cognitive trials (Cognizin) report small gains in attention and working memory at 250 to 500 mg/day
- •ICTUS trial (n=2,298) was negative on stroke recovery in the modern thrombolysis era
- •Lower per-gram choline content than alpha-GPC (~18% vs ~40%), meaning smaller TMAO load at equivalent dose
- •Long uridine half-life (~56 hours) supports once or twice daily dosing
Side-by-side
| Attribute | Bromantane | Citicoline |
|---|---|---|
| Category | nootropic | supplement |
| Also known as | Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine | CDP-choline, cytidine 5'-diphosphocholine, Cognizin |
| Half-life (hr) ↗ | 11 | 56 |
| Typical dose (mg) ↗ | 75 | 500 |
| Dosing frequency | daily, morning | 1 to 2 times daily |
| Routes | oral | oral, intravenous |
| Onset (hr) | 3 | 1 |
| Peak (hr) | 168 | 2 |
| Molecular weight | 280.21 | 488.32 |
| Molecular formula | C16H20BrN | C14H26N4O11P2 |
| Mechanism | Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. | Hydrolyzed to cytidine and choline after absorption; both cross the blood-brain barrier and are recombined intracellularly to reform CDP-choline, supporting phosphatidylcholine synthesis and acetylcholine production. |
| Legal status | Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK | Dietary supplement (US, Cognizin GRAS); prescription medication in most of the world |
| WADA status | banned | allowed |
| DEA / Rx | Not scheduled in the US | OTC supplement (US); Rx in most of the world |
| Pregnancy | Not recommended | Insufficient data for routine use |
| CAS | 87913-26-6 | 987-78-0 |
| PubChem CID | 9576456 | 13804 |
| Wikidata | Q4093816 | Q411470 |
Safety profile
Bromantane
Common side effects
- mild GI upset
- headache
- skin rash
- occasional insomnia at higher doses
Contraindications
- pregnancy
- lactation
- severe hepatic impairment
- severe renal impairment
- pediatric use
Interactions
- MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
- levodopa and dopamine agonists: additive dopaminergic activity(moderate)
- SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
- classical stimulants: theoretical additive activity, undocumented(moderate)
Citicoline
Common side effects
- mild GI upset
- headache
- restlessness
- occasional insomnia with evening dosing
Contraindications
- concurrent strong anticholinergic therapy
- established cardiovascular disease (TMAO concern, smaller than alpha-GPC)
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors: additive cholinergic effect(minor)
- antimetabolite chemotherapy (5-FU): theoretical cytidine pathway interaction(minor)
Which Should You Take?
Citicoline comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Bromantane is the right call when one of the conditionals below applies.
- → If your priority is fatigue resistance, pick Bromantane.
- → If your priority is stress and HPA-axis regulation, pick Bromantane.
- → If your priority is stroke recovery, pick Citicoline.
- → If your priority is choline supply, pick Citicoline.
Edge case: If you want to avoid controlled substance, Citicoline is the more accessible choice.
Default choice: Citicoline. Lower friction to source, and broader goal coverage. Reach for Bromantane only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Bromantane and Citicoline?
Bromantane and Citicoline differ in category (nootropic vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Bromantane or Citicoline?
Bromantane half-life is 11 hours; Citicoline half-life is 56 hours.
Can you stack Bromantane with Citicoline?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper